Basel Medical Group (NASDAQ: BMGL) reshapes board as Darren Tan replaces Jianing Lu

Rhea-AI Filing Summary

Basel Medical Group Ltd reported a change in its board of directors. The company appointed its Chief Commercial Officer, Mr. Tan Boon Chye (Darren), as a director on the board. He replaces Ms. Jianing Lu, who resigned as a director on the same day but continues to serve as the company’s Chief Financial Officer.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of March 2026

Commission File Number: 001-42527

Basel Medical Group Ltd

6 Napier Road,

Unit #02-10/11 Gleneagles Medical Centre

Singapore 258499

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Appointment and Resignation of Director

The board of directors of Basel Medical Group Ltd (Nasdaq: BMGL) (the “Company”) has appointed Mr. Tan Boon Chye (Darren), its Chief Commercial Officer, as a director on the board of the Company. Mr. Darren Tan was appointed to replace Ms. Jianing Lu, who resigned from the board of the Company on the same day. Ms. Lu’s appointment as the Chief Financial Officer of the Company continues and is not affected by such change of directorship.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Basel Medical Group Ltd
	By:	/s/ Darren Yen Feng Chhoa
	Name:	Dr. Darren Yen Feng Chhoa
	Title:	Chief Executive Officer
Date: March 30, 2026

FAQ

What corporate change did Basel Medical Group Ltd (BMGL) disclose in this 6-K?

Basel Medical Group Ltd disclosed a board change, appointing Chief Commercial Officer Mr. Tan Boon Chye (Darren) as a director. He replaces Ms. Jianing Lu, who resigned from the board but continues as the company’s Chief Financial Officer without any change to her executive role.

Who joined the board of directors of Basel Medical Group Ltd (BMGL)?

Chief Commercial Officer Mr. Tan Boon Chye (Darren) joined the board of Basel Medical Group Ltd as a director. His appointment fills the board seat previously held by Ms. Jianing Lu, aligning a senior commercial executive directly with the company’s board-level decision making.

Which director resigned from the Basel Medical Group Ltd (BMGL) board?

Ms. Jianing Lu resigned from the board of directors of Basel Medical Group Ltd. Despite stepping down as a director, she continues in her executive capacity as Chief Financial Officer, meaning the change affects only her board role, not her management responsibilities.

Does Ms. Jianing Lu remain Chief Financial Officer of Basel Medical Group Ltd (BMGL)?

Yes, Ms. Jianing Lu remains Chief Financial Officer of Basel Medical Group Ltd. The filing specifies that her CFO appointment continues and is not affected by her resignation from the board, so she retains responsibility for the company’s financial leadership and reporting.

What is Mr. Tan Boon Chye (Darren)’s role at Basel Medical Group Ltd (BMGL) after this filing?

Mr. Tan Boon Chye (Darren) serves as both Chief Commercial Officer and a director on the board of Basel Medical Group Ltd. This dual role combines operational commercial leadership with direct participation in board-level governance and strategic oversight for the company.

What type of SEC document did Basel Medical Group Ltd (BMGL) file for this update?

Basel Medical Group Ltd filed a Form 6-K, which is a report of a foreign private issuer used to provide current information. In this case, the document records the appointment of a new director and the corresponding resignation of a prior board member.